Bladder symptoms in multiple sclerosis: a review of pathophysiology and management

Bibliography

• Andersson KE, Chapple CR, Cardozo L, Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380-94
   PubMed Web of Science ®Google Scholar
• Nabi G, Cody JD, Ellis G, Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;4:CD003781
   PubMed Web of Science ®Google Scholar
• Martin-Merino E, Garcia-Rodriguez LA, Masso-Gonzalez EL, Roehrborn CG. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol 2009;182:1442-8
   PubMed Web of Science ®Google Scholar
• Athanasopoulos A, Perimenis P. Pharmacotherapy of urinary incontinence Int Urogynecol J Pelvic Floor Dysfunct 2009;20:475-82
   PubMed Web of Science ®Google Scholar
• Nicholas RS, Friede T, Hollis S, Young CA. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane database of systematic reviews 2009;1:CD004193
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
   PubMed Web of Science ®Google Scholar
• Fall M, Geirsson G, Lindstrom S. Discussion: functional classification of the overactive bladder. Urology 1997;50(Suppl 6A):34-5
   Web of Science ®Google Scholar
• Michel MC, Chapple CR. Basic mechanisms of urgency: preclinical and clinical evidence. Eur Urol 2009;56:298-308
   PubMed Web of Science ®Google Scholar
• Compston A, editor. McAlpine's multiple sclerosis, 4th edition. Churchill Livingstone, Oxford; 2005
   Google Scholar
• Weinshenker BG, Bass B, Rice GPA, The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989;112:133-46
   PubMed Web of Science ®Google Scholar
• Noseworthy JH. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999;399(6738 Suppl):A40-7
   PubMed Web of Science ®Google Scholar
• Koldewijn EL, Hommes OR, Lemmens WA, Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol 1995;154:169-73
   PubMed Web of Science ®Google Scholar
• Hennessey A, Robertson NP, Swingler R, Compston DA. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol 1999;246:1027-32
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Scivoletto G, Di Stasi SM, Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol Urodyn 1998;17:89-98
   PubMed Web of Science ®Google Scholar
• Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol 1999;161:743-57
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Scivoletto G, Di Stasi SM, Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch Phys Med Rehabil 1999;80:437-41
   PubMed Web of Science ®Google Scholar
• Gray R, Wagg A, Malone-Lee JG. Differences in detrusor contractile function in women with neuropathic and idiopathic detrusor instability. Br J Urol 1997;80:222-6
   PubMedGoogle Scholar
• Gallien P, Robineau S, Nicolas B, Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases. Arch Phys Med Rehabil 1998;79:255-7
   PubMed Web of Science ®Google Scholar
• Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB. Urodynamic pattern changes in multiple sclerosis. Urology 2001;57:239-45
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. Overactive bladder: an update. Curr Opin Urol 2007;17:231-6
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453-66
   PubMed Web of Science ®Google Scholar
• Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41:588-95
   PubMed Web of Science ®Google Scholar
• Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000;20:470-5
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31
   PubMed Web of Science ®Google Scholar
• Hebjorn S. Treatment of detrusor hyperreflexia in multiple sclerosis: a double-blind, crossover clinical trial comparingmethantheline bromide (Banthine), flavoxate chloride (Urispas) and meladrazine tartrate (Lisidonil). Urol Int 1977;32:209-17
   PubMed Web of Science ®Google Scholar
• Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986;135:966-68
   PubMed Web of Science ®Google Scholar
• Fader M, Glickman S, Haggar V, Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a Double-Blind, Randomized Crossover Trial. J Urol 2007;177:208-13
   PubMed Web of Science ®Google Scholar
• Ethans KD, Nance PW, Bard RJ, Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004;27:214-18
   PubMed Web of Science ®Google Scholar
• Horstmann M, Schaefer T, Aguilar Y, Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. J Urol 2006;25:441-5
   Google Scholar
• Amend B, Hennenlotter J, Schafer T, Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008;53:1021
   PubMed Web of Science ®Google Scholar
• Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10
   PubMedGoogle Scholar
• Appell RA, Sand P, Dmochowski R, Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358-63
   PubMed Web of Science ®Google Scholar
• Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420-9
   PubMed Web of Science ®Google Scholar
• Pelman RS, Capo JP Jr, Forero-Schwanhaeuser S. Solifenacin at 3 years: a review of efficacy and safety. Postgrad Med 2008;120:85-91
   PubMed Web of Science ®Google Scholar
• Arikian SR, Casciano J, Doyle JJ, A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface 2000;13:88-94
   PubMedGoogle Scholar
• Anonymous. Managing incontinence due to detrusor instability. Drugs Ther Bull 2001;39:59-64
   PubMedGoogle Scholar
• Chapple C, DuBeau C, Ebinger U, Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007;23:2347-58
   PubMed Web of Science ®Google Scholar
• Dorschner W, Stolzenburg JU, Griebenow R, Efficacy and cardiac safety of propiverine in elderly patients – a double blind, placebo-controlled clinical study. Eur Urol 2000;37:702-8
   PubMed Web of Science ®Google Scholar
• Mori S, Kojima M, Sakai Y, Nakajima K. Bladder dysfunction in dementia patients showing urinary incontinence: evaluation with cystometry and treatment with propiverine hydrochloride. Nippon Ronen Igakkai Zasshi 1999;36:489-94
   PubMedGoogle Scholar
• Stohrer M, Madersbacher H, Richter R, Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia – a double-blind, placebo-controlled clinical trial. Spinal Cord 1999;37:196-200
   PubMed Web of Science ®Google Scholar
• Ruscin JM, Morgenstern NE. Tolterodine use for symptoms of overactive bladder. Ann Pharmacother 1999;33:1073-82
   PubMed Web of Science ®Google Scholar
• Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005;3:CD005429
   PubMedGoogle Scholar
• Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database of Syst Rev 2007;4:CD003190
   PubMedGoogle Scholar
• Wood S, Coulson R. Adverse drug reactions on-line information tracking (ADROIT). Pharm Med 1993;7:203-13
   Google Scholar
• Alhasso AA, McKinley J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;4:CD003193
   PubMedGoogle Scholar
• McClurg D, Ashe RG, Marshall K, Lowe-Strong AS. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn 2006;25:337-48
   PubMed Web of Science ®Google Scholar
• Wallace S, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2004;1:CD001308
   PubMedGoogle Scholar
• De Ridder D, Vermeulen C, Ketelaer P, Pelvic floor rehabilitation in multiple sclerosis. Acta Neurologica Belgica 1999;99:61-4
   PubMed Web of Science ®Google Scholar
• Hay-Smith EJ, Bo K, Berghmans LC, Pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 2001;1:CD001407
   PubMedGoogle Scholar
• Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996;53:1270-5
   PubMed Web of Science ®Google Scholar
• Hoverd PA, Fowler CJ. Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;65:778-80
   PubMed Web of Science ®Google Scholar
• Dasgupta P, Haslam C, Goodwin R, Fowler CJ. The ‘Queen Square bladder stimulator’: a device for assisting emptying of the neurogenic bladder. Br J Urol 1997;80:234-7
   PubMedGoogle Scholar
• De Ridder D, Chandiramani V, Dasgupta P, Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow up. J Urol 1997;158:2087-92
   PubMed Web of Science ®Google Scholar
• Kalsi V, Gonzales G, Popat R, Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452-7
   PubMed Web of Science ®Google Scholar
• Fowler CJ, van Kerrebroeck PE, Nordenbo A, Van Poppel H. Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis). J Neurol Neurosurg Psychiatry 1992;55:986-9
   PubMed Web of Science ®Google Scholar
• The National Collaborating Centre for Chronic Conditions at the Royal College of Physicians. Multiple sclerosis: National clinical guideline for diagnosis and management in primary and secondary care. The Royal College of Physicians. The Royal College of Physicians, London; 2004
   Google Scholar
• Eustice S, Roe B, Paterson J. Prompted voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev 2000;2:CD002113
   PubMedGoogle Scholar
• Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001;185:56-61
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Panicker JN, Drake M, A UK consensus on the management of the bladder in multiple sclerosis. J Neurol, Neurosurg Psychiatry 2009:80;470-7
   PubMed Web of Science ®Google Scholar
• de Groat WC. A neurologic basis for the overactive bladder. Urology 1997;50(Suppl 6A):36-52
   PubMed Web of Science ®Google Scholar
• Rabey JM, Moriel EZ, Farkas A, Detrusor hyperreflexia in multiple sclerosis. Alleviation by a combination of imipramine and propantheline, a clinico-laboratory study. Eur Neurol 1979;18:33-7
   PubMed Web of Science ®Google Scholar
• Jensen D. Treatment of detrusor hyperreflexia in sclerosis multiplex. J Oslo City Hospital 1989;39:67-73
   PubMedGoogle Scholar
• Bennett N, O'Leary M, Patel AS, Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004;171:749-51
   PubMed Web of Science ®Google Scholar